Panacea Biotec LimitedQ1 FY27 Results & Financial Update
Panacea Biotec Limited: Q1 FY27 consolidated results and company financials – revenue ₹199.57 Cr, PAT ₹2.20 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Panacea Biotec price & chart
Market price₹360.50
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Panacea Biotec Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
During the quarter ended June 30, 2026, Panacea Biotec recorded consolidated revenue from operations of INR 199.57 crore and total income of INR 203.81 crore, driven by robust performance in its vaccine division.
Profitability turned positive at the consolidated level, with profit before tax (PBT) reaching INR 3.57 crore and profit after tax (PAT) touching INR 2.20 crore, resulting in a basic and diluted earnings per share (EPS) of INR 0.38.
The vaccines segment emerged as the primary growth engine for the quarter, generating INR 134.67 crore in revenue and recording a segment profit before tax of INR 7.47 crore, benefiting from higher long-term orders from key institutional customers.
The formulations segment recorded revenue of INR 64.90 crore but faced a segment loss before tax of INR 3.90 crore during the quarter.
Total expenses for the quarter stood at INR 202.98 crore, which included raw material consumption of INR 74.17 crore, employee benefit expenses of INR 44.16 crore, depreciation of INR 7.90 crore, and other operational expenses of INR 48.03 crore.
The company recognized exceptional income of INR 2.74 crore during the quarter, reflecting realizations from the remaining deferred consideration related to the past sale of domestic pharmaceutical brands.
Management prepared the financial results on a going concern basis, underpinned by surplus funds retained from historical brand monetization, positive group retained earnings, enhanced vaccine capacities, and secure institutional order flow.
01 · Business model
What does Panacea Biotec do?
Panacea Biotec Limited is an innovation-led biotechnology and pharmaceutical company engaged in research, development, manufacture and marketing of vaccines and pharmaceutical formulations.
The company's primary operational focus is centered around two major segments: Vaccines and Formulations, serving both institutional customers and commercial markets.
The group structure includes material subsidiaries such as Panacea Biotec Pharma Limited (PBPL) alongside other domestic and international operating entities spanning geographies like Germany, the United States, and regional markets.
Panacea Biotec leverages specialized manufacturing capabilities, proprietary drug substance facilities, and long-term supply arrangements with key institutional partners to generate its core revenue streams.
02 · Historical context
What shaped the business before this quarter
Surplus funds generated from the sale of domestic pharmaceutical formulations brands in India and Nepal in March 2022 have continuously strengthened the group's working capital position and funded vaccine capacity expansions.
The company executed a settlement agreement with Apotex Inc., USA on July 9, 2025, successfully resolving ongoing legal disputes and recording corresponding exceptional income in previous periods.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹199.57 Cr |
| Total income | ₹203.81 Cr |
| Profit before tax | ₹3.57 Cr |
| Profit after tax | ₹2.20 Cr |
| EPS | ₹0.38 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 1.1% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 1.8% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹4.24 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Higher long-term business orders for vaccines received from key institutional customers drove significant revenue expansion during the quarter.
Consolidated operational revenue of INR 199.57 crore was anchored by INR 134.67 crore from the vaccines business and INR 64.90 crore from pharmaceutical formulations.
What drove margins
Key expenditure items included raw and packing material consumption of INR 74.17 crore, inventory changes of INR 26.77 crore, employee benefits of INR 44.16 crore, and other expenses of INR 48.03 crore.
While the vaccines segment delivered a strong segment profit of INR 7.47 crore before tax, the formulations segment registered a segment loss of INR 3.90 crore.
05 · Demand, customers & order book
Where demand is coming from
The company fulfilled higher long-term business orders for vaccines from key institutional customers, directly translating into elevated quarterly revenues and operational profits.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Generated segment revenue of INR 134.67 crore and posted a profit before tax of INR 7.47 crore, supported by increased delivery volumes to key institutional buyers.
Contributed segment revenue of INR 64.90 crore with a segment loss before tax of INR 3.90 crore for the quarter.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Surplus funds from historical asset sales have been utilized to set up new facilities and enhance manufacturing capacities for vaccine drug substances.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The group continued to pursue business opportunities by scaling up its nutrition and pharmaceutical formulations business alongside core vaccine operations.
09 · Reported developments
What changed operationally
The group reported a positive consolidated profit after tax of INR 2.20 crore for Q1 FY27 compared to a loss in the corresponding previous periods.
Consolidated retained earnings as of June 30, 2026, remain positive, supporting ongoing operational expansion and business continuity.
10 · Pressure points & risks
What is not going smoothly
Standalone retained earnings of the parent company remained negative to the extent of INR 21,615 lakh as of June 30, 2026, noted by auditors as a factor indicating going concern uncertainties at the standalone level.
11 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Working capital position has been robustly supported by surplus liquidity retained from the March 2022 domestic brand sale.
12 · Beyond the numbers
What changed beyond the numbers
Reported update
Deferred Consideration Realization
The group recognized INR 2.74 crore of exceptional income during the quarter from the remaining deferred consideration for the sale of domestic pharmaceutical brands, leaving a balance deferred consideration of INR 7.45 crore to be recognized in subsequent periods.
Reported update
Annual General Meeting Schedule
The Board of Directors scheduled the 42nd Annual General Meeting of the company for Tuesday, September 29, 2026, via video conferencing, with book closure from September 25 to September 29, 2026.
13 · Key Q&A
The quarter, answered directly
What does Panacea Biotec do?
Panacea Biotec Limited is an innovation-led biotechnology and pharmaceutical company engaged in research, development, manufacture and marketing of vaccines and pharmaceutical formulations.
What is the clearest takeaway from Q1 FY27?
During the quarter ended June 30, 2026, Panacea Biotec recorded consolidated revenue from operations of INR 199.57 crore and total income of INR 203.81 crore, driven by robust performance in its vaccine division.
What drove revenue or demand?
Higher long-term business orders for vaccines received from key institutional customers drove significant revenue expansion during the quarter.
What mattered most for margins or profitability?
Key expenditure items included raw and packing material consumption of INR 74.17 crore, inventory changes of INR 26.77 crore, employee benefits of INR 44.16 crore, and other expenses of INR 48.03 crore.
What changed operationally beyond the headline numbers?
Surplus funds from historical asset sales have been utilized to set up new facilities and enhance manufacturing capacities for vaccine drug substances.
What are the main pressure points disclosed for the quarter?
Standalone retained earnings of the parent company remained negative to the extent of INR 21,615 lakh as of June 30, 2026, noted by auditors as a factor indicating going concern uncertainties at the standalone level.
14 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
15 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Deferred Consideration Recognition: Monitor the future recognition of the remaining balance deferred consideration of INR 7.45 crore categorized under contract liabilities in upcoming quarters.
- 02
Segment Turnaround in Formulations: Track operational progress and margin recovery in the formulations segment following its Q1 FY27 segment loss.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.